Oncology news & research | Hospital Healthcare Europe

This website is intended for healthcare professionals only.

Oncology

NICE approves cabozantinib for patients with advanced renal cell carcinoma

NICE approves cabozantinib for patients with advanced renal cell carcinoma

Ethicon launches power stapler enabling extra control and precision for complex surgeries

Positive opinion for tivozanib for the first-line treatment of advanced renal cell carcinoma in the EU

Positive opinion for tivozanib for the first-line treatment of advanced renal cell carcinoma in the EU

Survey reveals burden of myeloproliferative neoplasms on daily activity and ability to work

Survey reveals burden of myeloproliferative neoplasms on daily activity and ability to work

Data support the efficacy and safety of biosimilar rituximab in autoimmune disease and oncology

Data support the efficacy and safety of biosimilar rituximab in autoimmune disease and oncology

New radiopharmaceutical offers next-generation standard of diagnosis

New radiopharmaceutical offers next-generation standard of diagnosis

Olaparib maintenance therapy offers sustained quality of life and improved progression-free survival

Olaparib maintenance therapy offers sustained quality of life and improved progression-free survival

NICE publishes recommendation for everolimus in final draft guidance

NICE publishes recommendation for everolimus in final draft guidance

Hodgkin lymphoma survivors have more severe coronary artery disease post-chest irradiation

Hodgkin lymphoma survivors have more severe coronary artery disease post-chest irradiation

Proposed rituximab and etanercept biosimilars recommended for approval in Europe

Proposed rituximab and etanercept biosimilars recommended for approval in Europe

Tagrisso receives full approval in the EU

Tagrisso receives full approval in the EU

Broadened marketing authorisation for Darzalex in multiple myeloma recommended

Broadened marketing authorisation for Darzalex in multiple myeloma recommended

First biosimilar mAb in oncology is granted EU marketing authorisation

First biosimilar mAb in oncology is granted EU marketing authorisation

SMC accepts six new medicines for routine use in NHS Scotland

SMC accepts six new medicines for routine use in NHS Scotland

Biosimilars create opportunities for sustainable cancer care

Biosimilars create opportunities for sustainable cancer care

Tagrisso demonstrates superiority over chemotherapy in mutation-positive NSCLC

Tagrisso demonstrates superiority over chemotherapy in mutation-positive NSCLC

EU approval of Teva’s Trisenox® for first line treatment of low to intermediate risk APL

EU approval of Teva’s Trisenox® for first line treatment of low to intermediate risk APL

Lymphoseek may be alternative to elective neck dissection to stage oral cancer

Lymphoseek may be alternative to elective neck dissection to stage oral cancer

x